AMRZ Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 17.33
- PEG ratio
- 1.34
- P/B
- 2.07
- P/S (TTM)
- 2.27
- EV/EBITDA
- 11.92
Profitability & growth
- ROE (TTM)
- 10.1%
- Operating margin
- -3.5%
- Revenue growth YoY
- 4.7%
- Dividend yield
- 0.9%
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Amrize Ltd
Company profileAmrize Ltd (AMRZ) is an innovative technology firm at the forefront of the digital health and wellness industry, dedicated to transforming healthcare delivery with cutting-edge technologies and data-driven solutions. The company prioritizes enhancing patient outcomes and access to care, significantly investing in research and development to address the rising demand for scalable health innovations. With a diverse portfolio of products and strategic initiatives, Amrize is well-positioned to become a critical player in the ongoing evolution of healthcare, presenting a compelling investment…
Classification
- Sector
- Basic Materials
- Industry
- Building Materials
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- GRAFENAUWEG 8, ZUG, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
